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Sir,  
Recently, a study identified a mutation (c.176C > T, p.S59L) in the CHCHD10 gene as 
a cause of amyotrophic lateral sclerosis (ALS)/frontotemporal dementia (FTD) in a 
large pedigree with mixed phenotypes encompassing ALS, FTD, cerebellar ataxia and 
mitochondrial myopathy (Bannwarth et al., 2014).The same mutation was also found in 
a second kindred suffering from ALS, FTD and/or parkinsonian signs by the same 
authors. Additional mutations (p.R15L, p.P34S, p.G66V and p.P80L) have been 
subsequently reported in ALS and FTD with motor neuron disease (FTD-MND) 
patients (Chaussenot et al., 2014; Müller et al., 2014; Johnson et al., 2014; Kurzwelly et 
al., 2015; Ronchi et al. 2015; Chiò et al., 2015). More recently, the exon 2 of the 
CHCHD10 gene has been sequenced in a cohort of ALS, FTD, Parkinson´s disease and 
Alzheimer’s dementia, revealing two novel mutations (p.P23T and p.A35D) in two FTD 
patients (Zhang et al., 2015). Importantly, some of these screenings have not included 
neurologically healthy individuals from the same geographic origin (Bannwarth et al., 
2014; Müller et al., 2014; Johnson et al., 2014; Kurzwelly et al., 2015) and therefore, 
the real allele diversity within CHCHD10 might have been missed. This could have 
important consequences in terms of establishing firm conclusions on the genetic effects 
of rare alleles that have been identified in patients with ALS and/or FTD, and caution 
should be taken when generalising the outcomes to other populations and/or 
phenotypes. 
To further investigate the role of CHCHD10 in ALS/FTD disease spectrum, we Sanger 
sequenced its entire coding region in a comprehensive cohort of Spanish patients of 
1,224 subjects, distributed in three clinical phenotypes: ALS (n=423), FTD (n=709) and 
FTD-MND (n=92) (see table 1 for clinical and demographic description). Three-
hundred nineteen neurologically healthy and unrelated elderly individuals from Spain 
were also included (mean age at clinical assessment 70.84 ± 9.59 years, 36.5% female).  
Our mutation screening of CHCHD10 disclosed two novel mutations: a nonsynonimous 
change (c.34 C>T, p.P12S) in a patient with ALS and a nonsense mutation that resulted 
in a premature stop codon (c.244 C>T, p.Q82X) in a patient from the FTD cohort. None 
of these variants were present in our neurologically healthy control series nor in 
European samples from public databases, including the NHLBI Exome Sequencing 
Project (http://evs.gs.washington.edu/EVS), the Exome Aggregation Consortium 
(ExAC) (http://exac.broadinstitute.org) and the 1,000 Genome (1KG) Project 
Consortium (Abecasis et al., 2012), thus discarding the p.P12S and the Q82X mutations 
in a total of 35,470 and 61,386 chromosomes, respectively. 
The p.P12S substitution changes a conserved amino acid and is predicted, through in 
silico analysis, to be “disease causing” (MutationTaster, http://mutationtaster.org). The 
variant was identified in a male who developed a classical ALS phenotype of spinal 
onset at 58 years of age. The disease progression was slow and the patient died after 11 
years from a non-related cause, with no cognitive impairment. His father developed 
dementia of unknown aetiology at 70 years of age. 
The p.Q82X nonsense mutation, which would result in the loss of the entire CHCH 
domain of CHCHD10, was found in a female who, at age 58 years, started with short-
term memory problems, spatial disorientation and marked language difficulties. In 
particular she had reduced spontaneous speech, word finding difficulties and 
impairment in language comprehension. Formal neuropsychological evaluation revealed 
global and diffuse impairment. In the neurological exam 2 years after symptoms onset, 
asymmetrical rigidity and bradikynesia were noticed, but no resting tremor was 
detected. She scored 12 out of 30 in the Mini-Mental State Examination. Brain MRI 
revealed cortico-subcortical atrophy, more pronounced in the left fronto-insular region. 
After 3 years of onset, brain [
18
F] fluorodeoxyglucose-PET imaging showed left fronto-
temporo-parietal hypometabolism. Her mother died from an accident at 28 years of age 
and her father at 50 years old due to hepatic cirrhosis, with no signs of neurological 
disorders. 
Our analysis also revealed two previously reported nonsynonimous variants: p.P34S 
(rs551521196) and p.P96T (rs111677724). The p.P34S was identified in two ALS and 
four FTD patients, and the p.P96T was carried by four ALS and five FTD individuals. 
Interestingly, the p.P96T variant was presented in two ALS patients in a homozygous 
state. These two variants were also found in our control series (two control individuals 
presented the p.P34S and three harboured the p.P96T), and have been reported at low 
frequencies (<0.003) in European individuals from the 1KG Project Consortium and the 
ExAC databases. The fact that the p.P34S has been recently encountered in control 
subjects from USA/UK, Canada and Italy (Zhang et al., 2015), strongly indicates that 
this variant is not likely to be pathogenic. 
Including our two novel mutations, there are eight pathogenic variants in the CHCHD10 
gene that have been implicated in the ALS/FTD spectrum, seven of them within exon 2. 
These data suggest that mutations located in the exon 2 of CHCHD10 gene might be 
responsible for 0.86% of ALS, 0.34% of FTD and 0.95% of FTD-MND cases (Table 2).  
To our knowledge, this is the largest study performed to date aimed at evaluating the 
role of CHCHD10 in the ALS/FTD disease continuum. We report the first mutation in 
exon 1 and the first nonsense variant in this gene. Interestingly, the p.Q82X mutation 
was found in a patient presenting with atypical FTD with clinical features of progressive 
non-fluent aphasia together with parkinsonian signs and no motor neuron involvement. 
This complex phenotype reinforces the idea that mutations in CHCHD10 might cause a 
broader range of clinical presentations, and strengthens the hypothesis that 
mitochondrial functional impairment is implicated in several neurodegenerative 
disorders (Mattson et al., 2008). The second novel mutation (p.P12S) was found in a 
patient who suffered from ALS and died after 11 years of disease onset from an 
unrelated cause. Long disease duration and slow progression have been previously 
reported in other CHCHD10 mutation carriers (Kurzwelly et al., 2015; Müller et al., 
2015; Zhang et al., 2015), thus suggesting that these may be characteristic features 
related to CHCHD10 mutations. 
Table 1. Demographic and clinical characteristics of patients included in this study. 
 ALS (n=423) FTD (n=709) FTD-MND (n=92) 
Gender 
Male 
Female 
 
Age at onset (years) 
Mean ± SD (range) 
 
Family history 
Negative 
Positive 
 
FTD variant 
bvFTD 
PNFA 
SD 
 
Site of onset (ALS) 
Bulbar 
Limb 
 
56.3% 
43.7% 
 
 
59.57 ± 14.05 (23-89) 
 
 
78.26% 
21.74% 
 
 
- 
- 
- 
 
 
34.21% 
65.79% 
 
52.14% 
47.86% 
 
 
64.7 ± 10.25 (33-88) 
 
 
48.21% 
51.79% 
 
 
70.23% 
20.6% 
9.17% 
 
 
- 
- 
 
66.3% 
33.7% 
 
 
63.42 ± 11.68 (36-83) 
 
 
74.29% 
25.71% 
 
 
92.1% 
6.58% 
1.32% 
 
 
51.9% 
49.1% 
 Table 2. Frequency of pathogenic variants within exon 2 of the CHCHD10 gene. 
Protein 
position 
ALS 
(n=1,401) [%] 
FTD 
(n=876) [%] 
FTD-MND 
(n=211) [%] 
Total 
(n=2,488) [%] 
Controls 
(n=981) [%] 
p.R15L 7 [0.5] 0 [0] 0 [0] 7 [0.28] 0 [0] 
p.P23T 0 [0] 1 [0.11] 0 [0] 1 [0.04] 0 [0] 
p.A35D 0 [0] 1 [0.11] 0 [0] 1 [0.04] 0 [0] 
p.S59L 0 [0] 0 [0] 2 [0.95] 2 [0.08] 0 [0] 
p.G66V 1 [0.07] 0 [0] 0 [0] 1 [0.04] 0 [0] 
p.P80L 4 [0.29] 0 [0] 0 [0] 4 [0.16] 0 [0] 
p.Q82X 0 [0] 1 [0.11] 0 [0] 1 [0.04] 0 [0] 
total 12 [0.86] 3 [0.34] 2 [0.95] 17 [0.68] 0 [0] 
 
 
 
 
 
 
 
 
 
 
Table legends 
Table 1 
bvFTD: behavioural variant of FTD; PNFA: progressive non-fluent aphasia; SD: 
semantic dementia. 
Table 2 
In order to eliminate any possible bias due to genetic testing approaches (genotyping of 
a particular variant versus full sequencing of the coding exon), only control subjects 
from studies in which the entire exon 2 has been analysed have been included (Chiò et 
al., 2015; Zhang et al., 2015, and the present study). For the rest of phenotypes, data 
from Bannwarth et al., 2014; Chaussenot et al., 2014; Müller et al., 2014; Johnson et 
al., 2014; Kurzwelly et al., 2015; and Ronchi et al. 2015, have also been included. 
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